PetMed Express Q3 2024 GAAP EPS $(0.10), Sales $65.317M Beat $65.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
PetMed Express reported a Q3 2024 GAAP EPS loss of $(0.10) with sales of $65.317M, surpassing the $65.000M estimate. This represents a 10.95% increase in sales compared to the same period last year.
April 15, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PetMed Express reported a Q3 2024 GAAP EPS loss of $(0.10) but exceeded sales estimates with $65.317M, indicating a 10.95% increase from last year.
Beating sales estimates and showing significant year-over-year growth are positive indicators for PetMed Express. Despite the EPS loss, the sales performance and growth rate are likely to be viewed positively by investors, potentially leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100